Answers are grounded in this paper and cite their sources.
The LIBERTY study assessed the efficacy and safety of erenumab in participants with episodic migraine (EM) and 2-4 prior preventive treatment failures. The results have been presented after 3 years of erenumab exposure in its open-label extension phase (OLEP).
No takes yet. Share an insight, caveat, or question.
Reuter et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: